Advaxis (ADXS): Battle Against Cervical Cancer Progressing

Trading at under a dime, Advaxis Inc., (OTC: ADXS) stock should be on the list of penny stocks to watch, as we mentioned on Monday. ADXS, a leader in developing the next generation of immunotherapies for cancer and infectious diseases and winner of the 2012 Novartis Best Therapeutic Vaccine (approved or in development), announced today that it has completed enrollment of 40 patients in the 2nd of 3 dose cohorts in Lm-LLO-E7-07 assessing the safety and efficacy of ADXS-HPV for the treatment of cervical intraepithelial neoplasia (CIN) 2/3. ADXS shares are currently priced at -19.81% below the 50 day moving average, -30.59% below the 200 day moving average, -54.29% below the 52 week high of $0.21, and just 20.00% above the 52 week low of $0.08.

Looking for Hot Penny Stocks? Click here and get Alerts on the Best Penny Stocks FREE.

ADXS Stock Chart (1 month)

The patients in Advaxis’ cohort 2 were randomized 3:1 to ADXS-HPV (3 doses at 3.3×108 cfu) or placebo. The dose of ADXS-HPV in this cohort is 6X higher than that administered in cohort 1.

Patients are observed for a total of six months after the last dose before undergoing the standard of care surgery (LEEP) required for the treatment of this disease. Safety and efficacy results will be reported once all patients have completed LEEP.

ADXS continues to meet major milestones in their clinical development plan. The Company is optimistically looking forward to assessing the results of the 2nd cohort of this study and to advancing the development of ADXS-HPV for the treatment of HPV-associated diseases.

About ADXS-HPV Phase 2 Trial for CIN 2/3

This Phase 2 study is a randomized, single blind, placebo controlled study to assess the safety and efficacy of ADXS-HPV for the treatment of CIN 2/3. The study has three cohorts consisting of 40 patients each: 30 patients receive 3 doses of ADXS-HPV at 50 million7, 330 million or 1 billion cfu and 10 patients receive 3 doses of placebo. The primary objective of this study is to determine a safe dose of ADXS-HPV for the treatment of CIN 2/3.

Bottom Line: Biotech penny stocks can be the biggest gainers for those who have the patience to wait for the results to become public which, when positive, almost always skyrockets the PPS within minutes. ADXS is a strong buyout candidate by one of the pharmaceutical giants, was recently upgraded by Zacks, and will continue to be the top penny stock on our list of biotechs to watch.

Here is your opportunity to subscribe to the most elite penny stock newsletter.

Sign up with your email address now & get ready to make HUGE PROFITS on stocks that RUN.

(We are 100% Anti-Spam and will never rent or sell your information)

Last updated by at .

  Recent Penny Stock News